Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Joanne Sloan-Lancaster"'
Publikováno v:
Clinical Pharmacology in Drug Development. 7:759-772
Two phase 1 studies (TGAA and TGAB) evaluated the safety, pharmacokinetics, pharmacodynamics, and efficacy of LY3016859 (LY), a monoclonal antibody that binds epiregulin and transforming growth factor α (TGF-α), administered intravenously or subcut
Publikováno v:
The AAPS Journal. 16:1009-1017
Interleukin-1 beta (IL-1β) is an inflammatory mediator which may contribute to the pathophysiology of rheumatoid arthritis (RA) and type 2 diabetes mellitus (T2DM). Population pharmacokinetics (PK) of LY2189102, a high affinity anti-IL-1β humanized
Autor:
Andrea De Gaetano, William H. Landschulz, John Polzer, Jeffrey W. Miller, Eyas Abu-Raddad, Jolene K. Berg, Joel C Scherer, Joanne Sloan-Lancaster
Publikováno v:
Diabetes Care
OBJECTIVE Inflammation is associated with pancreatic β-cell apoptosis and reduced insulin sensitivity. Literature suggests that interleukin (IL)-1β may contribute to the pathogenesis of type 2 diabetes mellitus (T2DM). This study aimed to determine
Publikováno v:
Journal of the Renin-Angiotensin-Aldosterone System, Vol 18 (2017)
Journal of the Renin-Angiotensin-Aldosterone System: JRAAS
Journal of the Renin-Angiotensin-Aldosterone System: JRAAS
Introduction:LY3045697 is a potent and selective aldosterone synthase (CYP11B2) inhibitor that was developed as a safer alternative to mineralocorticoid receptor antagonists. Effects of LY3045697 on aldosterone and cortisol synthesis, as well as pota
Autor:
Yan Q. Chen, Joanne Sloan-Lancaster, David T. Berg, Julie Tseng-Crank, Mark A. Richardson, Brian W. Grinnell
Publikováno v:
Thrombosis and Haemostasis. 86:1563-1572
SummaryPlasminogen activator inhibitor-1 (PAI-1) is a serine protease inhibitor (SERPIN) specific for tissue-type and urokinase-like plasminogen activators. High plasma PAI-1 activity is a risk factor for thrombotic diseases. Due to the short half-li
Autor:
Jennifer Lippincott-Schwartz, Lawrence E. Samelson, Jan Ellenberg, John F. Presley, Joanne Sloan-Lancaster, Tetsuo Yamazaki
Publikováno v:
The Journal of Cell Biology
The nonreceptor protein tyrosine kinase ZAP-70 is a critical enzyme required for successful T lymphocyte activation. After antigenic stimulation, ZAP-70 rapidly associates with T cell receptor (TCR) subunits. The kinetics of its translocation to the
Publikováno v:
Cell. 92:83-92
Despite extensive study, several of the major components involved in T cell receptor-mediated signaling remain unidentified. Here we report the cloning of the cDNA for a highly tyrosine-phosphorylated 36-38 kDa protein, previously characterized by it
Publikováno v:
The Journal of Experimental Medicine
We previously demonstrated that altered peptide ligands (APL) can partially activate T cells, resulting in multiple distinct functional phenotypes, including the induction of anergy. Such APL stimulate a unique pattern of T cell receptor (TCR) phosph
Publikováno v:
Proceedings of the National Academy of Sciences. 91:2300-2304
T-cell activation by an immunogenic peptide can be antagonized by nonstimulatory analogs of that peptide. We investigated this T-cell receptor antagonism by using staphylococcal enterotoxin superantigen to stimulate hemoglobin-specific helper T (Th)
Publikováno v:
The Journal of Experimental Medicine
We have demonstrated Th2 clonal anergy as a consequence of partial T cell activation by immunogenic peptide and chemically fixed APC, as well as by altered peptide ligand and live antigen-presenting cells (APC). Either stimulation resulted in a profo